USPTO serial 79393467
NX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 15, 2025
- Examiner
- EDWARDS, ALICIA COLLINS
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with NX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Nicholas D. Wells
Nicholas D. Wells Legends Law Group, PLLC330 Main St.Kaysville, UT 84037United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Diagnostic biomarkers for analytical, research and scientific use; diagnostic biomarkers for in vitro testing for scientific use; diagnostic biomarkers for use in assessment of genomic analysis for scientific use; diagnostic biomarkers for use in assessment of individual diagnoses of cancer; diagnostic preparations for science or research; diagnostic reagents for science or research diagnostic reagents for the diagnosis of diseases; chemicals for the production of medical diagnostic reagents, particularly for cancer research | ACTIVE | — |
| 005 | Diagnostic preparations for medical purposes; diagnostic radiopharmaceutical preparations for medical purposes; pharmaceutical products, medical and veterinary preparations, namely, pharmaceutical preparations for use in the treatment of cancer; pharmaceutical preparations for the diagnosis and treatment of cancer; diagnostic pharmaceutical preparations; medical test kits comprising pharmaceutical preparations for individual medical diagnosis for cancer therapy; medical test kits comprising pharmaceutical preparations for use in oncology for cancer screening; medical test kits comprising pharmaceutical preparations for cancer diagnosis; medical test kits comprising pharmaceutical preparations for individual medical diagnosis in the field of protein imaging; Diagnostic test kits for use in oncology comprising pathology slides for testing tissue samples; test kits for use in oncology comprising sample tubes for testing tissue samples; diagnostic test kits comprising laboratory equipment for sample preparation, processing and storage for cancer diagnosis; diagnostic test kits for individual medical diagnosis comprising sample collection equipment for tumour analysis | ACTIVE | — |
| 009 | Recorded computer programs for use in oncology for analysing tissue samples from patients; downloadable computer programs for use in oncology for analysing tissue samples from patients; downloadable software for the analysis of medical data, particularly for cancer research, treatment and diagnosis; software for the analysis of medical data, particularly for cancer research, treatment and diagnosis; downloadable software for the digital representation of tumors and tumor features; software for the digital representation of tumors and tumor features; downloadable software for high- resolution digital image representation of the molecular composition of cellular anomalies; recorded software for high-resolution digital image representation of the molecular composition of cellular anomalies; downloadable software for high- resolution digital image representation of a digital tumor; recorded software for high- resolution digital image representation of a digital tumor; downloadable software for the analysis of medical data, particularly for cancer research, treatment and diagnosis; recorded software for the analysis of medical data, particularly for cancer research, treatment and diagnosis | ACTIVE | — |
| 010 | Apparatus for tumour diagnosis, namely, Imaging Mass Cytometry (IMC) apparatus; medical apparatus, namely, spectrometers for machine learning-based spectrum analysis of human blood plasma; Multiplex protein imaging scanners for medical diagnosis; apparatus for clinical diagnosis, namely, digital imaging device; spectrum analyzers for use in medical diagnosis; apparatus used in implementing diagnosis tests designed to detect abnormal genetic mutations in proteins, namely, spatial proteomics tools; diagnostic oncology apparatus for medical use, namely, digital imaging device; diagnostic, examination, and monitoring equipment, namely, multiplex protein imaging equipment; medical test kits comprising tissue sampling equipment for the use in oncology for cancer screening; medical test kits comprising tissue analysis tools for individual diagnosis in the field of cancer therapy | ACTIVE | — |
| 042 | Medical research in the field of cancer; medical research in the field of cancer diagnosis; Medical research in the field of proteomics; Medical research in the field of oncology; Medical research in the field of oncological diagnostics; technical data analysis services, namely, medical data analysis for cancer diagnostics; software-as-a-service (SaaS) featuring software for use in cancer diagnosis; platform-as-a-service (PaaS) featuring software for use in cancer diagnosis; software-as-a-service (SaaS) featuring software for cell analysis for use in oncology; platform-as-a-service (PaaS) featuring software for cell analysis for use in oncology; software-as-a-service (SaaS) featuring software for medical and scientific research in the field of cancer treatment and diagnosis; platform-as-a-service (PaaS) featuring software for medical and scientific research in the field of cancer treatment and diagnosis; software-as-a-service (SaaS) featuring software using machine learning in the field of medical diagnosis and research, particularly for cancer research, treatment and diagnosis; Platform as- a-service (PaaS) featuring software using machine learning in the field of medical diagnosis and research, particularly for cancer research, treatment and diagnosis; software-as-a-service (SaaS) featuring software for the analysis of medical data, particularly for cancer research, treatment and diagnosis; platform-as-a-service (PaaS) featuring software for the analysis of medical data, particularly for cancer research, treatment and diagnosis; software as-a-service (SaaS) featuring software for the digital representation of tumours and tumour features; platform-as-a-service (PaaS) featuring software for the digital representation of tumours and tumour features; software as-a-service (SaaS) featuring software for high- resolution digital image representation of the molecular composition of cellular anomalies; platform-as-a-service (PaaS) featuring software for high-resolution digital image representation of the molecular composition of cellular anomalies; software as-a-service (SaaS) featuring software for high- resolution digital image representation of digital tumors; platform-as-a-service (PaaS) featuring software for high- resolution digital image representation of digital tumors | ACTIVE | — |
| 044 | Pharmaceutical and medical consulting, particularly in the field of medical diagnostics and oncology; pharmaceutical and medical consulting for businesses in the medical and medical diagnostics field; pharmaceutical and medical consulting for cancer treatment; disease diagnosis services; cancer diagnosis services, particularly for enabling personalized and individual medical care; disease diagnosis services, particularly in the field of oncology; disease diagnosis services in the field of proteomics; medical analysis services for cancer diagnosis and prognosis; remote monitoring of medical data for medical diagnosis; medical analysis for the diagnosis and treatment of persons; remote monitoring of medical data for medical diagnosis and treatment; medical testing services relating to the diagnosis and treatment of disease; providing information in the field of cancer prevention, screening, diagnosis and treatment; medical diagnosis and treatment of cancer; testing and analysis services being medical diagnostic services; medical diagnostic services for the indication of individual treatments; medical diagnostic services for the indication of individual cancer treatments; medical diagnostic services for the indication of individual treatments in the field of oncology; providing information concerning diagnostic, prophylactic and therapeutic properties of pharmaceutical and biological products for prevention and treatment of diseases, disorders and conditions; medical services; veterinary services; hygienic care for human beings; hygienic care for animals | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Navignostics AG
- Other trademarks owned by Andrea Jacobs
- Other trademarks owned by Navignostics AG
- Other trademarks owned by Navignostics AG
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named NX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 23, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 26, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 6, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 5, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 15, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Sep 27, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Sep 10, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 10, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jul 15, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 15, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 27, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 27, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 21, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 28, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 2, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 2, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 2, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 26, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 4, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 4, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 1, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 30, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 6, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 6, 2024 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Apr 18, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 12, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 11, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |